Avanafil

113 interactions 1 explained in plain English 299 cited references

Also sold as: Stendra Stendra®

About Avanafil

Avanafil is used to treat erectile dysfunction (ED: impotence; inability to get or keep an erection in men). Avanafil is in a class of medications called phosphodiesterase (PDE) inhibitors. It works by increasing blood flow to the penis during sexual stimulation. This increased blood flow can cause an erection. Avanafi… Read the full Avanafil drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Nitroglycerin Transdermal Patch Isosorbide Mononitrate Amyl Nitrite Isosorbide Dinitrate Isosorbide Erythrityl Tetranitrate

17 Contraindicated 60 Major 36 Moderate

All (113) Contraindicated (17) Major (60) Moderate (36)

Contraindicated

Avanafil Amyl Nitrite Potentiation of hypotensive effects Details Avanafil Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Avanafil Erythrityl Tetranitrate Potentiation of hypotensive effects Details Avanafil Isosorbide Dilatrate®-SR Potentiation of hypotensive effects Details Avanafil Isosorbide Dinitrate Isochron Potentiation of hypotensive effects Details Avanafil Isosorbide Mononitrate Potentiation of hypotensive effects Details Avanafil Itraconazole Sporanox Increased avanafil exposure and an increased risk of avanafil-related adverse effects Details Avanafil Levoketoconazole Recorlev Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Avanafil Nitroglycerin Gonitro Potentiation of hypotensive effects Details Avanafil Pentaerythritol Tetranitrate Potentiation of hypotensive effects Details Avanafil Propatyl Nitrate Potentiation of hypotensive effects Details Avanafil Riociguat Adempas Increased risk of hypotension Details Avanafil Vericiguat Verquvo Increased risk of hypotension Details Avanafil Nitroglycerin Spray Nitrolingual Potentiation of hypotensive effects Details Avanafil Nitroglycerin Sublingual Nitrostat Potentiation of hypotensive effects Details Avanafil Nitroglycerin Topical Nitro-Bid Potentiation of hypotensive effects Details Avanafil Nitroglycerin Transdermal Patch Minitran® Patch Potentiation of hypotensive effects Details

Major

Avanafil Abametapir Increased exposure of CYP3A4 substrate Details Avanafil Adagrasib Krazati Increased CYP3A4 substrate exposure Details Avanafil Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Avanafil Atazanavir Reyataz Decreased avanafil clearance and increased avanafil plasma concentrations Details Avanafil Avacopan Tavneos Increased CYP3A4 substrate exposure Details Avanafil Boceprevir Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Carbamazepine Carbatrol Reduced avanafil exposure and reduced efficacy of avanafil Details Avanafil Clarithromycin Biaxin Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Cobicistat Tybost Increased avanafil exposure and increased risk of avanafil-related adverse events Details Avanafil Conivaptan Vaprisol Reduced avanafil clearance and increased avanafil exposure Details Avanafil Dabrafenib Tafinlar Reduced sensitive CYP3A4 substrate exposure Details Avanafil Darunavir Increased avanafil exposure and an increased risk of avanafil-related adverse reactions Details Avanafil Duvelisib Copiktra Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Avanafil Efavirenz Decreased avanafil plasma concentrations Details Avanafil Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Avanafil Erythromycin Erythrocin Stearate Increased avanafil exposure and an increased risk of avanafil-related adverse effects Details Avanafil Etravirine Intelence Altered avanafil plasma concentrations Details Avanafil Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Avanafil Fexinidazole An increased CYP3A4 substrate exposure Details Avanafil Fluconazole Diflucan Increased avanafil exposure Details Avanafil Fosnetupitant Increased exposure of CYP3A4 substrate Details Avanafil Idelalisib Zydelig Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Indinavir Decreased avanafil clearance and increased avanafil plasma concentration Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.